By Lucy Parkinson, Director of Research, LSN
RESI has always aimed to represent the diversity of capital sources for early stage life science companies; alongside sessions featuring VCs, pharma, angels, and other traditional sources of capital, LSN is proud to feature two sessions devoted to Family Offices that invest in new healthcare ventures. The Biotech Family Office sesssion features investors from five different firms who will cover the wide-ranging interests of family offices in the early stage drug development sector.
Moderated by Jayson Rieger (SVP of Business Development & Portfolio Management, PBM Capital), the panelists are:
If you’d be interested in hearing how these family offices source and assess biotech opportunities, and what you need to do to align your company with their investment ethos, you can register for RESI now.